Detalhe da pesquisa
1.
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Cancer
; 126(6): 1264-1273, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860140
2.
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Cancer
; 124(2): 306-314, 2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28960265
3.
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.
Lancet Haematol
; 7(2): e122-e133, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31837959
4.
Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype.
Leuk Res Rep
; 4(1): 28-30, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25973391